cenegermin: Clinical Trials

8 trials of cenegermin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 8 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 8
Phase 12Completed 2

Follow cenegermin: new trials by email Literature Review of cenegermin trials Research Report on cenegermin

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
rhNGF 5 μg/mL, rhNGF 10 μg/mL, Vehicle (Placebo solution) - Dry Eye Disease
Phase 2CompletedDompé Farmaceutici S.p.A3172024-01-222026-02-13
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle - Dry Eye Syndrome
Phase 2CompletedDompé Farmaceutici S.p.A2612019-06-102024-04-19
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
NGF, Vehicle - Dry Eye
Phase 2CompletedDompé Farmaceutici S.p.A1502017-01-202019-02-08
Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
rhNGF 180 µg/ml eye drops solution, vehicle eye drops - Retinitis Pigmentosa, Cystoid Macular Edema
Phase 2CompletedOspedale San Raffaele452015-05-012017-09-06
Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK
rhNGF 20µg/ml, Placebo - Neurotrophic Keratitis
Phase 2CompletedDompé Farmaceutici S.p.A482015-02-012022-12-08
Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye
rhNGF 20 µg/mL, rhNGF 4 µg/mL - Dry Eye Syndrome
Phase 2CompletedDompé Farmaceutici S.p.A402014-01-202024-04-19
A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)
rhNGF 60 µg/ml eye drops solution, rhNGF 180 µg/ml eye drops solution, Placebo - Retinitis Pigmentosa
Phase 1 / Phase 2CompletedDompé Farmaceutici S.p.A502014-01-012024-04-18
Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
rhNGF 10 μg/ml, rhNGF 20 μg/ml, vehicle - Neurotrophic Keratitis, Keratitis
Phase 1 / Phase 2CompletedDompé Farmaceutici S.p.A1742013-01-012024-04-19

Conditions studied

Dry Eye Syndromes (4)  ·  Retinitis Pigmentosa (2)  ·  Cone-Rod Dystrophies (1)  ·  Corneal Ulcer (1)  ·  Keratitis (1)  ·  Macular Edema (1)

Sponsors

Dompé Farmaceutici S.p.A (7)  ·  Ospedale San Raffaele (1)

Countries

Italy (4)  ·  United States (4)  ·  Austria (1)  ·  France (1)  ·  Germany (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Flavio Mantelli, MD, PhD (4)  ·  Francesco Sinigaglia, MD (1)  ·  Giacomina Massaro Giordano, MD (1)  ·  Paolo Rama, MD (1)  ·  William Lipsky, MD (1)

Results publications

PMID 26448169, PMID 30944103, PMID 39020305

NIH funding

2023 (1)